TEBU-BIO ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  4.7% 4.7% 2.2% 4.0% 2.9%  
Credit score (0-100)  46 45 64 50 52  
Credit rating  BB BB BBB BB BB  
Credit limit (kDKK)  0.0 0.0 0.1 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  661 1,170 1,499 1,122 1,578  
EBITDA  133 615 1,000 332 148  
EBIT  133 615 1,000 332 148  
Pre-tax profit (PTP)  110.0 604.9 976.3 279.0 91.1  
Net earnings  85.8 471.8 760.7 217.5 71.2  
Pre-tax profit without non-rec. items  110 605 976 279 91.1  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  211 683 923 391 462  
Interest-bearing liabilities  76.8 0.0 45.6 570 451  
Balance sheet total (assets)  577 1,593 1,623 1,260 1,357  

Net Debt  -118 -1,108 -778 137 -154  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  661 1,170 1,499 1,122 1,578  
Gross profit growth  1.0% 76.9% 28.1% -25.2% 40.7%  
Employees  1 1 1 1 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 100.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  577 1,593 1,623 1,260 1,357  
Balance sheet change%  -45.8% 176.2% 1.9% -22.4% 7.7%  
Added value  132.5 615.1 1,000.1 332.2 147.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  20.0% 52.6% 66.7% 29.6% 9.4%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  16.2% 56.7% 62.2% 23.0% 11.3%  
ROI %  25.3% 116.9% 116.7% 34.4% 15.8%  
ROE %  35.0% 105.6% 94.7% 33.1% 16.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  36.6% 42.9% 56.9% 31.0% 34.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -88.9% -180.2% -77.8% 41.2% -104.6%  
Gearing %  36.4% 0.0% 4.9% 145.7% 97.6%  
Net interest  0 0 0 0 0  
Financing costs %  8.4% 26.5% 104.1% 17.3% 11.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.6 1.9 2.3 1.4 1.5  
Current Ratio  1.6 1.9 2.3 1.4 1.5  
Cash and cash equivalent  194.6 1,108.1 823.9 433.0 605.8  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  193.5 744.6 918.9 386.4 457.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  133 615 1,000 332 74  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  133 615 1,000 332 74  
EBIT / employee  133 615 1,000 332 74  
Net earnings / employee  86 472 761 218 36